Biofrontera Inc. (BFRI) - Dilution Analysis

10-Q filing | 11.7M shares outstanding

10-K filing | 11.6M shares outstanding

10-Q filing | 10.8M shares outstanding

8-K filing: Biofrontera Inc. closed the second tranche of a private placement of Series C Preferred Stock, selling 2,500 shares at $1,000 per share for gross proceeds of $2.5 million. ($2.5M proceeds)

10-Q filing | 10.7M shares outstanding

S-1 filing: This is an S-1 filing for Biofrontera Inc. which includes information about the company, its business, the terms of its securities, and risk factors.

8-K filing: Biofrontera Inc. enters into a strategic transaction acquiring U.S. rights to Ameluz® and RhodoLED® in exchange for Series D Convertible Preferred Stock, and conducts a private placement of Series C Convertible Preferred Stock.

10-Q filing | 8.9M shares outstanding

10-K filing | 8.9M shares outstanding

S-1 filing: This S-1 filing relates to the offering and resale of up to 5,716,927 shares of common stock by the selling stockholders.

10-Q filing | 7.7M shares outstanding

10-Q filing | 5.1M shares outstanding

10-Q filing | 5.1M shares outstanding

S-1 filing: This prospectus relates to the offering and resale of up to 11,309,019 shares of common stock issuable upon the conversion of Series B-3 Convertible Preferred Stock and up to $7.4 million in net proceeds if the Preferred Warrants are exercised in full.

S-1/A filing: This prospectus relates to the offering and resale of common stock by selling stockholders.

10-K filing | 5.1M shares outstanding

S-1 filing: This prospectus relates to the offering and resale of 9,310,678 shares of common stock by the selling stockholders.

8-K filing: The company issued 6,586 shares of Series B-1 Convertible Preferred Stock and warrants to purchase 8,000 shares of Series B-3 Convertible Preferred Stock for $8.0 million and designated these preferred shares, subsequently converting 2,516,785 common shares and having a total of 5,089,413 shares outstanding. ($8.0M proceeds)

8-K filing: Biofrontera Inc. entered into securities purchase agreements to issue $6.6 million in Series B-1 Convertible Preferred Stock and $1.4 million in warrants to purchase Series B-3 Convertible Preferred Stock, with potential gross proceeds of up to $16 million if all warrants are exercised, to fund general business operations and Ameluz development. ($6.6M proceeds)

8-K filing: Biofrontera Inc. entered into an amendment regarding payments related to financial obligations. An institutional investor exercised pre-funded warrants to purchase 888,000 shares of common stock, completing the warrant exercise from a previous public offering. The total number of outstanding shares is now 2,572,628.

S-1/A filing: S-1/A filing for offering of common stock, warrants, and pre-funded warrants, with Roth Capital Partners, LLC as the placement agent.

S-1 filing: S-1 filing for offering of common stock and warrants.

8-K filing: Biofrontera, Inc. entered into a Settlement Agreement with Maruho Co. Ltd., resolving an arbitration proceeding. Biofrontera agreed to transfer 5,451,016 shares of stock of Biofrontera AG to Maruho as part of the settlement.

10-Q filing | 1.4M shares outstanding

8-K filing: Biofrontera Inc. completed a registered public offering on November 2, 2023, involving the sale of common stock and pre-funded warrants, along with an amendment to existing warrants, resulting in gross proceeds of approximately $4.5 million. ($0.0M proceeds)

S-1/A filing: This S-1/A filing describes an offering of up to 3,450,000 shares of common stock and up to 3,450,000 warrants to purchase up to 5,175,000 shares of our common stock, at a combined offering price of $ per share and accompanying warrant to purchase one and one-half shares of our common stock. and pre-funded warrants to purchase up to 3,450,000 shares of common stock.

S-1/A filing: This S-1/A filing describes an offering of up to 2,300,000 shares of common stock and up to 2,300,000 warrants to purchase up to 2,300,000 shares of common stock, as well as pre-funded warrants to purchase common stock with accompanying warrants.

S-1 filing: This SEC filing discusses stockholders' equity, including details of common stock, preferred stock, initial public offering, private placements, warrant exercises, adoption of a stockholder rights plan, and an exchange agreement.

10-Q filing | 1.4M shares outstanding

8-K filing: Stock split 1-for-20 | Outstanding: 26,699,002 → 1,334,950

10-Q filing | 26.7M shares outstanding

10-K filing | 26.7M shares outstanding

10-Q filing | 26.7M shares outstanding

8-K filing: The Company exercised options to acquire 2,623,365 ordinary shares of Biofrontera AG and purchased an additional 1,601,318 shares of Biofrontera AG on the open market, resulting in a total ownership of 4,224,683 shares, representing 7.45% of Biofrontera AG's outstanding shares as of November 8, 2022.

S-1 filing: This S-1 filing relates to the offering and resale of up to 7,433,757 shares of common stock by selling stockholders, consisting of shares issuable upon exercise of warrants and shares issued in a private placement.

8-K filing: Biofrontera Inc. entered into private exchange agreements to exchange 3,148,042 shares of the Company's common stock for AG Options representing the right to acquire 2,623,365 ordinary shares of Biofrontera AG.

10-Q filing | 23.6M shares outstanding

8-K filing: Biofrontera Inc. agreed to lower the exercise price of an existing warrant to $1.62 and issue a new warrant to purchase up to 4,285,715 shares of common stock, expecting to receive aggregate gross proceeds of approximately $4.69 million from the exercise of the existing warrant. ($4.69M proceeds)

POS AM filing: This Post-Effective Amendment No.2 is being filed to terminate the Registration Statement and deregister all of the securities registered under the Registration Statement that remain unsold as of the date hereof, consisting of 2,857,143 shares of the Registrant's common stock, par value $0.001 issuable upon the exercise of warrants to purchase a share of common stock at an exercise price of $5.25 per share held by the selling stockholder named in the Registration Statement.

S-1 filing: This S-1 filing relates to the offering and resale of up to 9,695,143 shares of common stock by the selling stockholder, including shares issued in private placements and shares issuable upon the exercise of outstanding warrants.

8-K filing: Biofrontera, Inc. completed a private placement, selling 1,850,000 shares of common stock, a warrant to purchase up to 3,419,000 shares of common stock, and a pre-funded warrant to purchase up to 1,569,000 shares of common stock for gross proceeds of $9,402,250. ($9.4M proceeds)

10-Q filing | 17.1M shares outstanding

10-K filing | 17.1M shares outstanding

S-1 filing: This prospectus relates to the offering and resale of up to 5,714,286 shares of common stock, including shares and shares issuable upon the exercise of outstanding warrants.

8-K filing: Biofrontera, Inc. closed a private placement on December 1, 2021, selling 1,350,000 shares of common stock, warrants to purchase up to 2,857,143 shares, and pre-funded warrants to purchase up to 1,507,143 shares at a combined purchase price of $15,000,000. ($15.0M proceeds)

10-Q filing | 11.6M shares outstanding

8-K filing: Biofrontera Inc. consummated its initial public offering of 3,600,000 units, each consisting of one share of common stock and one warrant, at a price of $5.00 per unit, with net proceeds estimated to be $15.4 million. ($18.0M proceeds)

S-1/A filing: This is an initial public offering of units, each unit consisting of one share of common stock of Biofrontera Inc. and one warrant to purchase one share of our common stock.

S-1/A filing: Biofrontera Inc. is offering 3,000,000 shares of its common stock in an initial public offering, with an estimated price range of $5.00 to $7.00 per share.

S-1/A filing: This is an initial public offering of shares of common stock of Biofrontera Inc. We are offering 3,000,000 shares of our common stock.

S-1/A filing: This is an initial public offering of shares of common stock of Biofrontera Inc. We are offering 3,000,000 shares of our common stock.

S-1/A filing: This is an initial public offering of shares of common stock of Biofrontera Inc.

S-1/A filing: This is an initial public offering of shares of common stock of Biofrontera Inc. We are offering 3,000,000 shares of our common stock.

S-1/A filing: This is an initial public offering of shares of common stock of Biofrontera Inc. We are offering 3,000,000 shares of our common stock.

S-1/A filing: This is an initial public offering of shares of common stock of Biofrontera Inc.

S-1/A filing: This is an initial public offering of shares of common stock of Biofrontera Inc.

S-1/A filing: This is an initial public offering of shares of common stock of Biofrontera Inc.

S-1/A filing: This is an initial public offering of shares of common stock of Biofrontera Inc.

S-1 filing: This is an initial public offering of shares of common stock of Biofrontera Inc.